1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bioptik Technology, Inc.

Bioptik Technology, Inc.

TTPEX:4161
21.25
TWD
-0.15
(-0.70%)
1.82EPS
12.40P/E
1.38BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.68
7.39
7.31
7.71
7.7
8.77
9.89
8.48
12.88
13.4
14.39
14.95
14.47
15.68
Basic EPS, GAAP
1.52
0.53
0.45
0.12
-0.54
0.45
0.09
-1.05
0.39
0.85
1.49
1.62
1.23
1.86
Free Cash Flow per Basic Share
-0.74
-2.24
-1.73
-1.07
-0.84
-0.17
0.22
-0.12
-1.06
0.66
3.04
2.48
0.64
1.48
Dividend per Share
- -
- -
0.83
0.4
0.81
- -
0.42
0.51
0.25
0.25
- -
0.64
0.27
- -
Book Value per Share
10.73
13.45
16.56
15.77
14.48
14.04
13.32
12.75
12.05
12.49
13.69
15.07
16.21
16.53
Tangible Book Value per Share
10.71
13.43
16.54
15.76
14.47
14.02
13.29
12.74
12.04
12.48
13.68
15.06
16.16
16.48
Basic Weighted Avg Shares
52
56
62
62
62
59
57
57
57
57
58
58
58
58
Sales/Revenue/Turnover
452
415
453
477
476
520
566
486
738
768
829
865
837
913
Operating Margin (%)
10.93
6.42
12.31
3.71
1.04
0.14
0.08
-9.01
4.8
5.11
10.89
10.4
7.95
7.77
Depreciation Expense
18
22
23
27
33
33
41
38
37
33
35
36
33
33
Net Income, GAAP
79
30
28
8
-34
26
5
-60
23
48
86
94
71
109
Effective Tax Rate (%)
13.02
27.19
34.65
47.8
- -
27.66
- -
- -
- -
25.12
20.56
16.3
18.14
15.56
Profit Margin (%)
17.51
7.15
6.14
1.61
-7.08
5.08
0.93
-12.35
3.06
6.32
10.35
10.81
8.5
11.89
Working Capital
317
466
538
454
574
452
388
269
250
253
355
417
451
461
LT Debt
- -
78
38
- -
325
311
311
259
219
179
155
133
112
101
Total Equity
613
809
1,040
1,038
887
812
768
736
695
718
824
905
975
993
Return on Invested Capital (%)
7.2
2.29
3.05
0.67
- -
0.1
- -
- -
- -
2.13
5.19
5.5
3.87
4.28
Return on Capital (%)
14.28
4.33
2.66
0.95
- -
2.45
- -
- -
- -
4.12
7.01
7.58
5.62
8.42
Return on Common Equity (%)
16.84
4.29
3.06
0.75
-3.54
3.14
0.67
-8.03
3.18
6.9
11.17
10.88
7.61
11.44

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
358
360
366
LT Borrowings
111
106
101
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
1,492
1,459
1,382

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
936
943
989
Cash, Cash Equivalents & STI
448
379
443
Accounts Receivable, Net
38
51
65
Inventories
203
229
220
Total Current Liabilities
484
517
528
Payables & Accruals
- -
- -
- -
ST Debt
358
360
366
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.28%
6.02%
7.67%
Free Cash Flow
41.26%
185.84%
-74.05%
Net Income, GAAP
-207.2%
7.8%
-23.92%
Sales/Revenue/Turnover
7.42%
13.02%
-3.25%
Total Cash Common Dividend
- -
- -
-57.18%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
220
208
210
228
865
2025
196
190
215
236
837
2026
224
238
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
0.5
0.31
0.5
1.62
2025
0.26
0.07
0.45
0.45
1.23
2026
0.3
0.66
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.64
2025
- -
- -
- -
- -
0.27
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chin Chang Yang
Full Time Employees
80
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 188, Jhonghua South Road Miaoli Taiwan 35057
IPO Date
Jul 29, 2011
Website
bioptik.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bioptik Technology Incorporation Bioptik Technology Incorporation engages in the research, development, manufacturing, wholesale, and retail of biotechnology and medical equipment, including multi-functional diagnostic devices, health supplements, skincare products, and pet healthcare solutions, primarily in Taiwan and internationally. The company offers EasyMate blood glucose monitoring systems; blood glucose, cholesterol, uric acid, and hemoglobin monitoring systems and corresponding test strips; hyaluronic acid-based skincare products; dietary supplements in forms such as powders, tablets, capsules, beverages, and jellies featuring ingredients like astaxanthin; beauty care lines focused on whitening, radiance, firming, and anti-aging; and pet blood glucose monitors with rapid test kits for blood sugar, infectious diseases, and other health indicators. Bioptik Technology Incorporation, founded in 1999 and headquartered at No. 188, Jhonghua South Road, Zhunan Township, Miaoli County, Taiwan, operates production facilities in Zhunan for medical devices and reagents, Hsinchu for skincare, and Tainan for bioenergy developments including biodiesel, astaxanthin, and cellulose bioethanol; it maintains three R&D departments supporting OEM and ODM services for medical testing, dietary supplements, and cosmetics. The company, a publicly listed entity on the Taipei Exchange under ticker 4161, continues to expand its global sales of core monitoring systems and strips while emphasizing innovations in home health management for chronic conditions like high blood pressure, cholesterol, and blood sugar, alongside diversified offerings in beauty and pet care without notable recent acquisitions, partnerships, or major strategic shifts reported in the past one to two years.